Ivermectin’s Treatment of Disease Progression
Ivermectin, a well-known antiparasitic medication, has been approved by the World Health Organization and US Food and Drug Administration.
It’s used extensively in LMICs (low- and middle-income countries) to treat worm infections.2,3 It also treats scabies and lice.
The total amount of ivermectin available is estimated to be about one-third the world’s current population.5
Since the start of the SARS/CoV2 pandemic in , both observational and randomized studies have evaluated ivermectin’s effectiveness as a treatment and prophylactic against COVID-19.
iverheal 12mg vs Remdesivir Comparison
The Front Line COVID-19 Critical Care Alliance reviewed 27 studies that evaluated the effects of ivermectin in the prevention and treatment of COVID-19-related infection.
A review concluded that Iverheal 12 or Iverheal 6 “demonstrates a strong signal of therapeutic effectiveness” against COVID-19.9 However, the National Institutes of Health of the United States recently declared that
“There is not enough evidence to support the use of ivermectin in COVID-19 treatments,” 11 as well as the recommendation that the World Health Organization discouraged the use of the drug outside of clinical trials.12
Ivermectin’s antiviral properties have been demonstrated against a variety of DNA and RNA viruses including Zika yellow fever and dengue.14 Caly and coworkers14 demonstrated that SARS-CoV-2 can be used to kill cells.16
There are other theories about the mechanism. These include the inhibition 3CLPro activity at SARS-CoV-21718,18 (a protease necessary for replication of the virus), and a range of anti-inflammatory effects19. Also, the competitive binding to ivermectin, as demonstrated in many in silico studies.20 This could prevent the virus from binding to ACE-2 receptors which would suppress the spread.
Ivermectin, Emerging Oral COVID-19 Treatments
Hemagglutination via viral binding to sialic acid receptors in erythrocytes is a new pathological process.
Both host-directed and virus-directed mechanisms were proposed. The mechanism used in clinical practice may be multimodal. It could depend on the stage and severity of the disease. A thorough review of all the mechanisms involved is necessary.
It could take many years to develop new drugs. It is therefore crucial to identify any existing drugs that can be used to fight COVID-19. Drugs with a proven safety record over years of use may be key to reducing, eradicating, or even preventing the SARS/CoV-2 epidemic.
Why you Still Shouldn’t Take Ivermectin For COVID-19
It could take many months or even years before vaccine-free humanity, particularly among those living in LMIC countries.
Ivermectin can be purchased in many countries around the world and is readily available.6 Ivermectin tablets are currently priced at $2.90 per 100 mg.
This is why it is important for people with limited resources to explore the effectiveness of ivermectin in fighting SARS-CoV-2. It is possible to use it as a treatment for COVID-19. It is important to compare the cost-effectiveness and effectiveness of ivermectin with other treatment options and prophylaxes.
We reviewed the references of the studies and two additional 2021 reviews on ivermectin.9 As well as the WHO report which included an analysis of ivermectin 12.
We reached professionals in the area (Drs. Andrew Hill and Pierre Kory, along with Paul Marik), for information about recent trial results.
Additional trials were also reviewed on registries of clinical trials. Trialists for the 39 in progress trials or studies that were not classified as classified were contacted to obtain information about the status of trials, trial data, and trial data.
Many preprint publications and non-published articles were identified with Preprint Servers, MedRkhiv, Research Square, and the International Clinical Trials Registry Platform. Each study that was excluded from the full-text review was noted.
Analysis of data
We extracted information or data on study design (including methods, location, sites, funding, study author declaration of interests, and inclusion/exclusion criteria), setting, participant characteristics (disease severity, age, gender, comorbidities, smoking, and occupational risk), and intervention and comparator characteristics (dose and frequency of ivermectin/comparator).
The main outcome of the intervention portion of the review was deaths due to any cause and the presence of COVID-19 as determined by the investigators to determine the need of ivermectin-based prophylaxis.
Other outcomes included the time from polymerase chain reactions (PCR), negative and clinical recovery time, length stay in the hospital, admission to ICU (for outpatient care) or admission to the hospital.
Is ivermectin appropriate for mild Covid-19 treatment?
Mechanical ventilation. The duration of mechanical ventilation. Post-hoc evaluations on improvement or deterioration. .
We requested clarification from the authors in the event of a conflict between data from different sources within one study (eg, the difference between the published paper and the registry of trials), T.L., T.D., or A.B. was involved in the assessments. The Cochrane RCT risk of bias instrument was used. Discrepancies were settled through discussions.
Continuous outcomes were evaluated using the mean difference (95% confidence intervals) (CI), and the dichotomous results (RR/CI).
No missing data was entered into the results. The authors were contacted by to clarify study methodology and any missing data.
